Symposium 16: Clinical follow-up: new guidelines and consensus
DOI:
https://doi.org/10.47196/diab.v56i3Sup.593Keywords:
autoimmune, diabetes mellitusAbstract
Immune-mediated diabetes in adults is a challenge in its diagnosis, as well as its differentiation from type 2 diabetes and LADA.
In the follow-up and treatment of this population, an intensified insulin therapy is the ideal regimen of insulin replacement to reaches glycemic targets, in order to avoid the development and progression of macro and microvascular complications, minimizing episodes of hypoglycemia and providing strategies to ensure adequate quality of life with reduction of the psychosocial burden of living with diabetes. In addition to capillary glycemic self-monitoring and HbA1c, there are currently new technological tools: interstitial and real-time glucose sensors and new insulin analogs, integrated insulin infusion systems with sensor and closed hybrid systems.
References
I. Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021;44:2589-2625.
II. Battelino T, Danne T, Bergenstal R, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care 2019;42:1593-1603.
III. Buzzetti R, Tuomi T, Didac M, Pietropaolo M, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 2020;69:2037-2047.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
